Where is cx30 made

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: The Connexin 30 (Cx30) protein is not manufactured in a single location but is produced within cells throughout the human body, primarily in the inner ear, skin, and brain. It is encoded by the GJB6 gene located on chromosome 13q12, with its expression regulated by cellular mechanisms rather than industrial production. Research on Cx30 has been conducted globally, with significant studies published from institutions in the United States, Europe, and Japan since its discovery in the 1990s.

Key Facts

Cx30 is encoded by the GJB6 gene on chromosome 13q12, identified in 1997
Mutations in GJB6 cause hearing loss, affecting approximately 1 in 1,000 newborns globally
Cx30 forms gap junctions with 30-40 connexin proteins, allowing passage of molecules up to 1 kDa
In the inner ear, Cx30 is expressed in supporting cells of the cochlea from embryonic development
Over 50 different mutations in GJB6 have been linked to autosomal dominant and recessive hearing loss

Overview

Connexin 30 (Cx30), also known as gap junction beta-6 protein, is a crucial component of cellular communication systems in humans and other vertebrates. It belongs to the connexin family of proteins that form gap junctions—specialized channels allowing direct transfer of ions, nutrients, and signaling molecules between adjacent cells. First identified in 1997 through genetic studies, Cx30 has since been recognized for its vital roles in hearing, skin function, and neurological processes. The protein's discovery emerged from research into hereditary hearing loss, revealing its significance in maintaining cochlear homeostasis.

The production of Cx30 occurs naturally within human cells rather than through industrial manufacturing. Its synthesis begins with transcription of the GJB6 gene, located on the long arm of chromosome 13 (13q12). This genetic locus spans approximately 5.4 kilobases and contains two exons that encode the 261-amino acid protein. Unlike pharmaceuticals or consumer goods, Cx30 isn't "made" in factories but is expressed in specific tissues including the inner ear's supporting cells, epidermal keratinocytes, and astrocytes in the brain. Research into its production mechanisms has advanced through molecular biology techniques developed since the 2000s.

How It Works

Cx30 functions by assembling into hexameric structures called connexons that dock with counterparts on neighboring cells to form complete gap junction channels.

Structural Assembly: Each Cx30 protein molecule has four transmembrane domains that assemble with five other copies to form a connexon. Six connexins create a channel with a pore diameter of approximately 1.5-2.0 nanometers, allowing passage of molecules up to 1 kilodalton in size. The complete gap junction contains hundreds to thousands of these channels clustered in plaque-like formations on cell membranes.
Cellular Localization: Cx30 primarily localizes to plasma membranes at sites of cell-cell contact. In the inner ear, it's abundantly expressed in supporting cells of the organ of Corti, particularly Deiters' cells and pillar cells. These gap junctions create a network called the epithelial gap junction system that facilitates potassium recycling—a process essential for maintaining the endocochlear potential of +80 mV required for hearing.
Regulation Mechanisms: Cx30 expression and channel activity are tightly regulated through phosphorylation at specific serine and tyrosine residues. The protein has a relatively short half-life of 1.5-5 hours, requiring continuous synthesis. Channel gating is controlled by voltage, pH, and calcium concentrations, with complete closure occurring at intracellular calcium levels above 10⁻⁵ M.
Genetic Control: The GJB6 gene promoter contains response elements for various transcription factors including AP-1 and SP1. Expression begins during embryonic development around week 12 in humans and continues throughout life. Alternative splicing can produce minor variants, though the major isoform remains constant across tissues.

Key Comparisons

Feature	Cx30 (GJB6)	Cx26 (GJB2)
Chromosomal Location	13q12	13q12 (adjacent)
Protein Size	261 amino acids	226 amino acids
Primary Tissue Expression	Inner ear, skin, brain	Inner ear, skin, liver
Hearing Loss Mutations	~50 documented	~100 documented
Channel Conductance	~90 pS	~110 pS
Discovery Year	1997	1990

Why It Matters

Hearing Preservation: Cx30 is essential for auditory function, with mutations causing up to 50% of non-syndromic hearing loss cases in some populations. The protein facilitates potassium recycling in the cochlea, preventing accumulation that would damage sensory hair cells. Without functional Cx30, the endocochlear potential drops below +40 mV, rendering hearing impossible.
Skin Barrier Function: In the epidermis, Cx30 forms gap junctions between keratinocytes that coordinate differentiation and barrier formation. Studies show that Cx30-deficient mice exhibit delayed wound healing and compromised skin integrity. The protein represents approximately 15% of total connexins in human epidermis.
Neurological Implications: Cx30 in astrocytic networks helps regulate extracellular potassium in the brain, maintaining proper neuronal excitability. Research indicates altered Cx30 expression may contribute to epilepsy and other neurological conditions, with animal models showing increased seizure susceptibility when Cx30 is absent.

Looking forward, research continues to explore therapeutic approaches targeting Cx30 dysfunction. Gene therapy trials for GJB6-related hearing loss are in preclinical stages, while pharmacological modulators of gap junction communication show promise for skin and neurological disorders. As our understanding of connexin biology deepens, Cx30 remains a focal point for developing treatments for conditions affecting millions worldwide. The next decade may see breakthroughs in connexin-specific drugs that could restore function in tissues where Cx30 plays its critical roles.